The low EOMES/TBX21 molecular phenotype in multiple sclerosis reflects CD56+ cell dysregulation and is affected by immunomodulatory therapies

F.C. Mckay; P.N. Gatt; N. Fewings; G.P. Parnell; S.D. Schibeci; M.A.I. Basuki; J.E. Powell; A. Goldinger; Marzena Pedrini; Allan Kermode; T. Burke; S. Vucic; G.J. Stewart; D.R. Booth

doi:10.1016/j.clim.2015.12.015

The low EOMES/TBX21 molecular phenotype in multiple sclerosis reflects CD56+ cell dysregulation and is affected by immunomodulatory therapies

F.C. Mckay, P.N. Gatt, N. Fewings, G.P. Parnell, S.D. Schibeci, M.A.I. Basuki, J.E. Powell, A. Goldinger, Marzena Pedrini, Allan Kermode, T. Burke, S. Vucic, G.J. Stewart, D.R. Booth

Centre for Neuromuscular and Neurological Disorders (Perron Institute)

Research output: Contribution to journal › Article › peer-review

18 Citations (Scopus)

Abstract

© 2016 Published by Elsevier Inc. Multiple Sclerosis (MS) is an autoimmune disease treated by therapies targeting peripheral blood cells. We previously identified that expression of two MS-risk genes, the transcription factors EOMES and TBX21 (ET), was low in blood from MS and stable over time. Here we replicated the low ET expression in a new MS cohort (p

Original language	English
Pages (from-to)	96-107
Number of pages	12
Journal	Clinical Immunology
Volume	163
Early online date	4 Jan 2016
DOIs	https://doi.org/10.1016/j.clim.2015.12.015
Publication status	Published - 1 Feb 2016

Access to Document

10.1016/j.clim.2015.12.015

Cite this

Mckay, F. C., Gatt, P. N., Fewings, N., Parnell, G. P., Schibeci, S. D., Basuki, M. A. I., Powell, J. E., Goldinger, A., Pedrini, M., Kermode, A., Burke, T., Vucic, S., Stewart, G. J., & Booth, D. R. (2016). The low EOMES/TBX21 molecular phenotype in multiple sclerosis reflects CD56+ cell dysregulation and is affected by immunomodulatory therapies. Clinical Immunology, 163, 96-107. https://doi.org/10.1016/j.clim.2015.12.015

@article{e771cbd14cfb4eb7b12da96dc274d382,

title = "The low EOMES/TBX21 molecular phenotype in multiple sclerosis reflects CD56+ cell dysregulation and is affected by immunomodulatory therapies",

abstract = "{\textcopyright} 2016 Published by Elsevier Inc. Multiple Sclerosis (MS) is an autoimmune disease treated by therapies targeting peripheral blood cells. We previously identified that expression of two MS-risk genes, the transcription factors EOMES and TBX21 (ET), was low in blood from MS and stable over time. Here we replicated the low ET expression in a new MS cohort (p",

author = "F.C. Mckay and P.N. Gatt and N. Fewings and G.P. Parnell and S.D. Schibeci and M.A.I. Basuki and J.E. Powell and A. Goldinger and Marzena Pedrini and Allan Kermode and T. Burke and S. Vucic and G.J. Stewart and D.R. Booth",

year = "2016",

month = feb,

day = "1",

doi = "10.1016/j.clim.2015.12.015",

language = "English",

volume = "163",

pages = "96--107",

journal = "Clinical Immunology",

issn = "1521-6616",

publisher = "Academic Press",

}

Mckay, FC, Gatt, PN, Fewings, N, Parnell, GP, Schibeci, SD, Basuki, MAI, Powell, JE, Goldinger, A, Pedrini, M , Kermode, A, Burke, T, Vucic, S, Stewart, GJ & Booth, DR 2016, 'The low EOMES/TBX21 molecular phenotype in multiple sclerosis reflects CD56+ cell dysregulation and is affected by immunomodulatory therapies', Clinical Immunology, vol. 163, pp. 96-107. https://doi.org/10.1016/j.clim.2015.12.015

TY - JOUR

T1 - The low EOMES/TBX21 molecular phenotype in multiple sclerosis reflects CD56+ cell dysregulation and is affected by immunomodulatory therapies

AU - Mckay, F.C.

AU - Gatt, P.N.

AU - Fewings, N.

AU - Parnell, G.P.

AU - Schibeci, S.D.

AU - Basuki, M.A.I.

AU - Powell, J.E.

AU - Goldinger, A.

AU - Pedrini, Marzena

AU - Kermode, Allan

AU - Burke, T.

AU - Vucic, S.

AU - Stewart, G.J.

AU - Booth, D.R.

PY - 2016/2/1

Y1 - 2016/2/1

N2 - © 2016 Published by Elsevier Inc. Multiple Sclerosis (MS) is an autoimmune disease treated by therapies targeting peripheral blood cells. We previously identified that expression of two MS-risk genes, the transcription factors EOMES and TBX21 (ET), was low in blood from MS and stable over time. Here we replicated the low ET expression in a new MS cohort (p

AB - © 2016 Published by Elsevier Inc. Multiple Sclerosis (MS) is an autoimmune disease treated by therapies targeting peripheral blood cells. We previously identified that expression of two MS-risk genes, the transcription factors EOMES and TBX21 (ET), was low in blood from MS and stable over time. Here we replicated the low ET expression in a new MS cohort (p

U2 - 10.1016/j.clim.2015.12.015

DO - 10.1016/j.clim.2015.12.015

M3 - Article

C2 - 26762769

SN - 1521-6616

VL - 163

SP - 96

EP - 107

JO - Clinical Immunology

JF - Clinical Immunology

ER -

The low EOMES/TBX21 molecular phenotype in multiple sclerosis reflects CD56+ cell dysregulation and is affected by immunomodulatory therapies

Abstract

Access to Document

Fingerprint

Cite this